Blog | Veristat Insightful Perspectives

Is it Possible to Gain Regulatory Approval Following a Single-Arm Study?

In this case study example - yes.

Veristat developed a thorough regulatory submission strategy and novel efficacy endpoint for the treatment of an ultra-rare and aggressive hematologic malignancy that led to FDA and EMA approval following a single-arm phase I/II study.

Read More

Veristat Joined the Battle Again - in 2022

Another Successful Cycle for Survival Ride Raising $90K To Support Rare Cancer Research


Read More